Información del artículo
El Texto completo está disponible en PDF
Bibliografía
[Vargas, in press]
Partial growth hormone deficiency. A Vargas.
[Shalet, in press]
Diagnosis of partial growth hormone deficiency in adults. SM Shalet.
[Toogood, in press]
Clinical implications of partial growth hormone deficiency in adults. AA Toogood.
[Leger, in press]
GH deficiency in childhood persisting as a partial form in adulthood. J Leger.
[Mauras, in press]
Lessons learned: from genetic causes of hypopituitarism. N Mauras.
[Vallette, in press]
Congenital ACTH deficiency: lessons learned from Tpit. S Vallette.
[Crowley, in press]
Broadening spectrum of hypogonadotropic hypogonadism. WF Crowley.
[Brue, in press]
The many faces of hypopituitarism and LHX4 mutations. TC Brue.
[Hwa, in press]
Unraveling the complexities of growth. V Hwa.
[Hirschhorn, in press]
What have we learned from genome-wide analysis studies? JN Hirschhorn.
[Jorge, in press]
GH pharmacogenetics: predicting response to GH treatment. AAL Jorge.
[Bouc, in press]
Epigenetic, genomic imprinting and regulation of growth. Y Le Bouc.
[S65-2]
Experimental models of pituitary growth hormone deficiency and correction with interfering RNAs. ICAF Robinson.
[Ho and Jorgensen, in press]
Management issues in clinical GH replacement. K Ho, JO Jorgensen.
[Hughes, in press]
Management of hypopituitarism in transition. IA Hughes.
[Monson, in press]
Integration of hormonal replacement in hypopituitarism. JP Monson.
[OR39-4]
Hypopituitarism with chronic use of opiods. MB Gordon, MS Gordon.
[OR28-2]
Comparing recurrence and enlargement of non-functioning pituitary adenomas in hypopituitary patients with and without long-term growth hormone replacement therapy. DS Olsson, M Buchfelder, S Schlaffer, B-A Bengtsson, K-E Jakobsson, G Johannsson, et al.
[OR28-2]
Comparing recurrence and enlargement of non-functioning pituitary adenomas in hypopituitary patients with and without long-term growth hormone replacement therapy. DS Olsson, M Buchfelder, S Schlaffer, B-A Bengtsson, K-E Jakobsson, G Johannsson, et al.
[OR28-5]
Reduced growth hormone secretion contributes to increased cardiovascular risk and is associated with a more severe metabolic phenotype in obesity. H Makimura, T Stanley, D Mun, C Chen, SK Grinspoon.
[OR35-1]
Integrity of the somatotrope GH/IGF-1 axis is required for normal thymus function: a clinical study in patients with adult GH deficiency. G Morrhaye, H Kermani, R Cheynier, H Martens, V Geenen.
[P1-118]
Melatonin appraisal in childhood pineal lesions. NA Greggio, C Sperandio, P Sartorato, M Calderone, PA Battistella.
[P1-237]
Pituitary natriuretic peptide signaling via guanylyl cyclase-B (GC-B) receptors in gh3 somatolactotropes is regulated by protein phosphatase-mediated desensitization but not receptor internalization. IR Thompson, A Waltho, JA Lambertucci, CJ Wheeler-Jones, RC Fowkes.
[P1-134]
Spironolactone hydrochlorothiazide a novel combination in the treatment of nephrogenic diabetes insipidus. S Somuri, A Sacerdote, G Bahtiyar, J Mejia.
[P1-344]
Testicular volumes according to bone age in Korean boys. S Yang, IT Hwang, JS Lim.
[P1-394]
Association of mitochondrial function with reduced growth hormone levels and cardiovascular disease risk in obesity. H Makimura, D Mun, M Kron, M Hrovat, D Systrom, A Fleischman, et al.
[P1-673]
Clinical and hormonal outcome following surgery for non functioning pituitary adenomas (NFA): experience from a single Australian center. C Caputo, P McNeill, KW Ng, J Yang, W Inder.
[P1-675]
Treatment outcomes of pituitary tumors at the university of Santo Tomas Hospital: 2004-2008. JS Fonte, EC Cunanan, BJ Matawaran, LB Mercado-Asis.
[P2-151]
OTX and EMX genes in pituitary gland development and function. AH Mortensen, ML Brinkmeier, SW Davis, F Castinetti, MA Potok, SA Camper.
[P1-691]
Growth hormone administration reduces visceral adiposity and HsCRP in patients with growth hormone deficiency following cure of acromegaly: A randomized, placebo-controlled study. KK Miller, TL Wexler, P Fazeli, LE Gunnell, G Graham, BMK Biller, et al.
[P1-722]
Pharmacokinetic, pharmacodynamic and safety results of ALTU-238, a long-acting, crystalline recombinant human growth hormone, in healthy adults. KM Attie, KS Loveday, D Froim, SK Basu.
[P1-724]
Hypothyroidism in pediatric patients treated with recombinant human growth hormone. KN Wong, LL Levitsky, M Misra.
[P1-725]
Four year efficacy and safety data of treatment with omni-trope 5mg/ml lyophilized formulation in children with growth failure due to growth hormone deficiency. F Peter, T Romer, B Koehler, E Solyom, M Walczak, A Muzsnai, et al.
[P1-729]
Short-term effects of weekly based slow releasing growth hormone (GH) on abdominal obesity patients. S-W Kim, M-K Kwon, M-A Jung, J-H Noh, B-J Kim, S Chon, et al.
[P1-731]
GH therapy increases prolactin (PRL) levels in PRL insufficient and GH deficient adult survivors of childhood acute lymphoblastic leukaemia (ALL). C Follin, K Link, C Moell, T Wiebe, J Bjork, EM Erfurth.
[P1-732]
One year of growth hormone therapy improves body composition in adults with Prader-Willi syndrome. R Sode-Carlsen, J Bollerslev, J Sandahl Christiansen, S Farholt, KF Rabben, C Hoybye.
[P3-136]
Low and low normal IGF-1-Levels in patients with chronic medical disorders (CMD) is independent of anterior pituitary deficiencies of LH, FSH and TSH: Implications for treating CMD using IGF-1 as a diagnostic marker. ER Braverman, K Blum, M Kerner, R Kennedy, M Dispensa, S Kern, et al.
[P2-729]
Mutations in the five muscarinic cholinergic receptor genes are absent in familial isolated GH deficiency type IB. A Mohamadi, M Martari, JA Phillips, P Mullis, R Salvatori.
[P2-730]
A homozygous mutation in the promoter region of growth hormone gene (GH1) in 3 siblings is associated with isolated growth hormone deficiency (IGHD). LR Carvalho, AAL Jorge, R Martin, M Franca, E Costalonga, L Montenegro, et al.
[P2-733]
Sex variation in bone responsiveness to growth hormone replacement in adult GH-deficient patients. A Rossini, R Lanzi, M Losa, C Molinari, S Palmieri, A Pulcina, et al.
[P2-736]
Urine albumin excretion is normal in growth hormone (GH) deficient adults but decreases after GH replacement. CRP Oliveira, JAS Barreto-Filho, RA Meneguz-Moreno, R Salvatori, VP Araujo, RMC Pereira, et al.
[P2-738]
Adiponectin and leptin levels in adults with congenital untreated isolated growth hormone deficiency. CRP Oliveira, MH Aguiar-Oliveira, R Salvatori, RMC Pereira, RA Meneguz-Moreno, EHA Valenca, et al.
[P2-739]
Normal final height after late growth hormone treatment of patients with growth hormone deficiency. M Franca, E Costalonga, A Jorge, L Carvalho, B Mendonca, I Arnhold.
[P2-740]
L-dopa revisited: performance characteristics of l-dopa in the evaluation of adult growth hormone deficiency. HR Mogul, C Boradia, M Frey, I Weiss.
[P2-742]
Isolated GH deficiency of adult-onset in the kims database: prevalence, response to GH therapy, and evolution to multiple pituitary hormone deficiencies. V Popovic, FF Casanueva, R Abs, M Koltowska-Haggstrom, B Jonsson, B Saller, et al.
[P2-745]
Are currently employed growth hormone doses sufficient to provide cardiovascular benefits in growth hormone deficient adults? KA Frisch, CB Newman, B Rosenzweig, R Roubenoff, M Rey, T Kidder, et al.
[P2-748]
Growth hormone deficiency in adults: the use of quality of life to determine access to gh replacement therapy fails to discriminate an adverse cardiovascular risk profile. A Aragon-Alonso, M Sherlock, E McGregor, R Murray, PM Stewart, AA Toogood.
[P2-749]
Use of an oral ghrelin-mimetic GH secretagogue as a simple diagnostic test for adult GH deficiency. GR Merriam, KCJ Yuen, P Asberry, V Bonert, A Dobs, JM Garcia, et al.
[P2-750]
Female gender and low IGF-I SDS are risk factors for low bone mass in adult growth hormone deficiency A KIMS database analysis. NA Tritos, D King, A Hamrahian, DM Cook, PJ Jonsson, MP Wajnrajch, et al.
[P3-130]
Bioactive IGF-1 levels in obesity. J Frystyk, D Brick, A Gerweck, AL Utz, KK Miller.
[P3-418]
Identification and characterization of V2R mutations causing partial or complete nephrogenic diabetes insipidus (NDI) in two thai families. T Sahakitrungruang, M-K Tee, N Rattanachartnarong, V Shotelersuk, K Suphapeetiporn, WL Miller.
[P3-547]
T3 Measurement has no role in assessing whether hypothyroid patients on levothyroxine (T4) treatment are over-replaced. K Duxbury, M Guy, J Kane, AH Heald, A Rudenski.
[P3-624]
Pituitary deficiency, especially severe growth hormone deficit (GHD), is associated with the classical adverse lipid profile of hypopituitarism in patients with traumatic brain injury (TBI). E Yollin, O Kozlowski, E Merlen, M Rousseau, P Fontaine, C Cortet-Rudelli.
[P3-625]
Preliminary results of french collaborative evaluation (DEPHY-TC) in patients with suspected pituitary abnormalities after traumatic brain injury (TBI) and sub arachnoid hemorrhage (SAH). G Raverot, MF Malezet, S Carlier, B Morlet-Barla, M Picot, A Tabarin, et al.
[P3-626]
Predictors of hypopituitarism after ischemic stroke. M Bondanelli, AR Carli, A Bertocchi, MR Ambrosio, S Ceruti, S Lavezzi, et al.
[P3-627]
Traumatic injury to the brain endocrine evaluation a year after the event (The TRIBE Study). JF Robles, JV Navarro, ML Maglinao, BJ Matawaran, AA Andag-Silva, LB Mercado-Asis.
[P3-629]
Molecular analysis of GATA2 gene in three siblings with gonadotrope and thyrotrope hormonal deficiency. M Moreira, C Boguszewski, AC Latronico, LR Carvalho.
[P3-631]
Bone mineral density and bone markers in patients with idiopathic central diabetes insipidus. EA Pigarova, LY Rozhinskaya, NI Sazonova, GS Kolesnikova.
[P3-633]
Molecular analysis of pituitary transcription factors in a patient with combined pituitary hormone deficiency and median cleft palate. DC Moraes, MNC Pinheiro, MM Costa, FL Conceicao, M Vaisman, TM Ortiga-Carvalho.
[P3-635]
Clinical insights into the performance of the glucagon stimulation test (GST) in the assessment of the hypothalamic-pituitary-adrenal axis (HPA). LA Behan, WYL Thong, F Finucane, G Falk, CJ Thompson, A Agha.
[P3-643]
Correlation of biochemical tests with the quality of life of patients with growth hormone deficiency following traumatic brain injury or subarachnoidal haemorrhage. A Mueller-Oeffner, B Gutt, T Siegmund, M Hufnagl, P-M Schumm-Dreager.
[P3-644]
Gradual onset partial hypopituitarism following previous head trauma. PH Williams, R Law, KJA Kumar, PA Goulden.
[P3-645]
Severe hyponatremia associated with hypopituitarism due to hemorrhagic fever with renal syndrome: a case study. S Lee, LY Lee, KY Lee, YS Kim, IB Park, YJ Cho, et al.
[P3-646]
Granulomatous hypophysitis presenting with secondary adrenal insufficiency and hypercalcemia with iodine induced hyperthyroidism. RA McCauley, LF Amorosa, SH Schneider, X Wang.
[P3-647]
Lymphocytic hypophysitis and typical germinoma two cases of young males with diabetes insipidus associated with a suprasellar mass. OPR Hamnvik, ER Laws, UB Kaiser.
[P3-648]
Hypopituitarism caused by intravascular lymphoma: a case report. AL Carlson, JL Leahy.
[P3-650]
Unique clinicopathological appearance of lymphocytic hypophysitis in a young male presenting with elevated serum IGF-1. C Chadha, ER Seaquist.
[P3-651]
A Case of Sheehan's syndrome with autoimmune thyroiditis and hypercalcemia. A Yoshihara, M Sue, N Masai, N Watanabe, R Sigemitsu, H Ueshiba, et al.
[P3-670]
Primary central nervous system lymphoma presenting as panhypopituitarism and diabetes insipidus secondary to hypothalamic mass. J Lim, V Kalyanaram, M Baker, H Scofield.
[P3-671]
Diabetes insipidus as an initial clinical manifestation of pineal germinoma: an adult case study. S-M Son, S-Y Kim, D-W Lee, Y-H Kang.
[P3-692]
Endoscopic transsphenoidal pituitary surgery in forty patients with a growth hormone secreting macroadenoma. MAEM Wagenmakers, RT Netea-Maier, EJ van Lindert, GF Pieters, JA Grotenhuis, ARMM Hermus.
[P3-695]
Effects of dopamine agonists on growth hormone secretion in prolactinoma patients. J Ullal, DW Richardson.
[P3-700]
Thyroxin replacement therapy does not improve growth velocity in children with subclinical hypothyroidism and short stature. VL Zen, MA Czepielewski, LP de Paula, JC Schwerz.
[P3-711]
De novo missense mutation (Ala37Pro) in vasopressin V2 receptor (AVPRV2) caused partial nephrogenic diabetes insipidus (NDI) followed as psychogenic polydipsia. M Yokoyama, J-I Nagaishi, A Hayashi, F Miyahara, M Fujimoto, Y Kawashima, et al. Recopilación de contenidos: Dra. Eugenia Resmini.
Copyright © 2010. Sociedad Española de Endocrinología y Nutrición
